On September 7, 2021 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported that new oncology data will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, which will be held 16-21 September, 2021 (Press release, Hoffmann-La Roche, SEP 7, 2021, View Source [SID1234587290]). With one of the broadest oncology pipelines and portfolios in the industry, Roche presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung cancer, and a presentation on cancer of unknown primary (CUP), which has been selected for inclusion in the ESMO (Free ESMO Whitepaper) Press Programme.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our data at ESMO (Free ESMO Whitepaper) 2021 show how we continue to pursue potentially transformative advances in breast and lung cancer, particularly in earlier stage settings where the chance for cure is highest," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. "Furthermore our efforts in personalised healthcare, exemplified by our insights in CUP, will help address the needs of many patients who are diagnosed at a late stage."

Breast Cancer Highlights
First phase II data will be presented from an interim analysis of giredestrant, a next-generation oral selective oestrogen receptor degrader (SERD), in neoadjuvant, ER-positive, HER2-negative early breast cancer. Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Our efforts in this area represent a step towards making the treatment of patients with HR-positive breast cancer more effective and less debilitating in order to reduce the burden of treatment. This study further showcases Roche’s commitment to identifying meaningful treatment options for patients with breast cancer through a comprehensive development programme that includes early and late-stage HR-positive, HER2 positive and triple-negative forms of the disease.

Lung Cancer Highlights
New results from the phase III IMpower010 study, to be presented during Presidential Symposium Three, highlight patterns of relapse and subsequent therapy following treatment with Tecentriq (atezolizumab) versus standard of care in early lung cancer, and help to define how Tecentriq fits into the adjuvant treatment pathway. These findings are particularly important as real-world data, which will also be presented at ESMO (Free ESMO Whitepaper), will provide detail on the proportion of people with early NSCLC in the United States who do not receive adjuvant treatment despite guidelines recommending that they do so. These real world data also highlight survival outcomes in this setting and reinforce the need for more effective adjuvant therapy in NSCLC, as half of all people with early-stage lung cancer today still experience disease recurrence following surgery.

The phase III IMpower010 study showed adjuvant Tecentriq improved disease-free survival in PD-L1-positive early-stage lung cancer, compared with best supportive care – a first in cancer immunotherapy. Based on the outcomes from this study, the United States Food and Drug Administration recently granted Priority Review under the Real-Time Oncology Review pilot programme to Tecentriq as an adjuvant treatment for certain people with early NSCLC, and is expected to make a decision later this year.

Innovation in Personalised Healthcare
Latest results from a preliminary descriptive molecular analysis based on the CUPISCO study, which will be featured in the ESMO (Free ESMO Whitepaper) Press Programme, shed further light on the genomic profiles of patients with poor-prognosis CUP. These results highlight the importance of comprehensive genomic profiling for patients with CUP and identify therapeutically relevant genomic alterations in a significant proportion of patients, which may help to inform a more personalised treatment plan. In CUP, doctors cannot identify the location of the original (primary) tumour and can only find metastases. This causes practical problems since traditional treatment approaches rely on the site of origin being known, and as such, most patients are treated with nonspecific chemotherapy. Unfortunately, prognosis remains poor and the median survival following diagnosis is just six to 12 months, reinforcing the need for improved diagnosis and treatment.

Real world data from the United States examining the use of Foundation Medicine’s comprehensive genomic testing prior to first-line therapy in patients with metastatic colorectal cancer (mCRC) will also be presented and underpin Roche’s efforts to drive more widespread and earlier testing for patients with cancer.

Ahead of ESMO (Free ESMO Whitepaper), Roche will also be hosting a virtual Personalised Healthcare in Oncology Symposium for healthcare professionals on Thursday 9 September, 13:00 – 14:30 CEST. In this symposium, different healthcare system experts from across the world will discuss how new and emerging solutions in personalised healthcare can help to improve patient outcomes, and ultimately their quality of life.

LinkedIn Live event – COVID-19 and Cancer: Reshaping Patient Care in the Context of the Pandemic Today and Tomorrow
Roche will also be hosting a live roundtable discussion on Wednesday 15 September 2021, 16:00 CEST that will focus on the global efforts to overcome the impact of the COVID-19 pandemic on cancer outcomes. The discussion, featuring experts from medical societies, academia and patient groups, will focus on what lessons have been learned so far, and how stakeholders can forge new paths and partnerships to find and deliver solutions for patients and society. Join this event on Roche’s LinkedIn page here.

Roche Oncology Newsroom
Roche’s ESMO (Free ESMO Whitepaper) Oncology Newsroom will be available from Tuesday 7 September for journalists to access exclusive materials sharing insights into Roche’s latest data, vision and strategy to pursue and advance scientific progress in order to improve the lives of people living with cancer. To access the newsroom, please register here.

Keep up to date with ESMO (Free ESMO Whitepaper) news and updates by using the hashtag #ESMO21 and follow Roche on Twitter via @Roche and LinkedIn.

Overview of key presentations featuring Roche medicines

Medicine Abstract title Abstract or presentation number
Breast cancer
Giredestrant Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase 2 coopERA BC study LBA14
Kadcyla Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase 3 EMILIA study 284P
Kadcyla Trial in progress – ASTEFANIA: A phase 3 study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy 202TiP
Kadcyla Trial in progress – KATE3: A phase 3 study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer 329TiP
Real world data Real-world Outcomes of Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) metastatic Breast Cancer (mBC) with High Tumor Mutational Burden (hTMB) Treated with Immune Checkpoint Inhibitors (ICI) 237P
Lung cancer
Tecentriq IMpower010: Patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC) LBA9
Tiragolumab Trial in progress – SKYSCRAPER-03: Phase III, Open-Label Randomised Study of Atezolizumab + Tiragolumab vs Durvalumab in Patients with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed After Platinum-based Concurrent Chemoradiation (cCRT) 1190TiP
Atezolizumab Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first line (1L) advanced/metastatic (m)NSCLC: results of the Blood First Assay Screening Trial (BFAST) Phase 3 Cohort C 1281O
Real world data Real-world Adjuvant Treatment Patterns and Survival Outcomes among early NSCLC US Patients 1158P
Real world data Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting 1650P
Bladder cancer
Atezolizumab Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC) 658MO
Gastric cancer
Atezolizumab Phase Ib/II open-label, randomised evaluation of second-line atezolizumab (atezo) + linagliptin (lina) vs ramucirumab (ram) + paclitaxel (pac) in MORPHEUS-Gastric Cancer 1382P
Head and neck cancer
Tiragolumab Trial in progress – SKYSCRAPER-09: A Phase II, Randomised, Double-blinded Study of Atezolizumab (Atezo) + Tiragolumab (Tira) and Atezo + Placebo as First-line (1L) Therapy for Recurrent/Metastatic (R/M) PD-L1+ Squamous Cell Carcinoma of the Head and Neck (SCCHN) 927TiP
Hepatocellular carcinoma
Atezolizumab IMbrave150: exploratory efficacy and safety results in patients with hepatocellular carcinoma without macrovascular invasion (MVI) or extrahepatic spread (EHS) treated with atezolizumab (atezo) + bevacizumab (bev) or sorafenib (sor) 932P
Tumour agnostic treatment and personalised healthcare
Comprehensive genomic profiling Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO 1804P
Comprehensive genomic profiling Fusion and rearrangement (RE) detection using DNA and RNA-based comprehensive genomic profiling (CGP) of sarcomas 1532P
Comprehensive genomic profiling Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations 457P
Tumour agnostic Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN 80P
Real world data Comprehensive genomic profiling (CGP) and PD-L1 IHC in patients (pts) with advanced non-small cell lung cancer (aNSCLC): Testing and Treatment Patterns in the real-world (RW) setting 1301P
Real world data Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) 477P

About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa(alectinib); Avastin(bevacizumab); Cotellic(cobimetinib); Erivedge(vismodegib); Gavreto(pralsetinib); Gazyva/Gazyvaro(obinutuzumab); Herceptin(trastuzumab); Kadcyla(trastuzumab emtansine); MabThera/Rituxan(rituximab); Perjeta(pertuzumab); Polivy(polatuzumab vedotin); Tarceva(erlotinib); Rozlytrek(entrectinib); Tecentriq(atezolizumab); Venclexta/Venclyxto(venetoclax) in collaboration with AbbVie; Xeloda(capecitabine); Zelboraf(vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.